$0.16
(Market cap
$5,928 Mln
Revenue (TTM)
$827 Mln
P/E Ratio
--
P/B Ratio
1743.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-77.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
6.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.4
-
Face value
--
-
Shares outstanding
82,949,338
10 Years Aggregate
CFO
$-1,382.00 Mln
EBITDA
$-1,701.30 Mln
Net Profit
$-3,012.65 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PTC Therapeutics (PTCT)
| -7.4 | -2.9 | 2.0 | 52.8 | 6.5 | 12.9 | 26.2 |
|
BSE Sensex
| -11.2 | -4.2 | -10.2 | -8.7 | 7.0 | 8.4 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
PTC Therapeutics (PTCT)
| 68.3 | 63.1 | -27.8 | -4.2 | -34.7 | 27.1 | 39.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PTC Therapeutics (PTCT)
|
70.3 | 5,928.4 | 827.1 | -186.7 | -8.4 | -- | -- | 1,743.3 |
| 73.2 | 10,799.5 | 622.0 | -300.9 | -30.1 | -62 | -- | 16.7 | |
| 238.0 | 14,697.4 | 867.5 | 506.6 | -2.8 | -- | 26.9 | 25.7 | |
| 76.5 | 10,298.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 48.7 | 12,600.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.3 | |
| 98.2 | 12,586.4 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 293.3 | 8,707.3 | 417.3 | 225.0 | 42.8 | 18.6 | 39.5 | 7.1 | |
| 511.8 | 11,846.5 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.6 | |
| 419.9 | 12,047.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.5 | 20.2 | |
| 320.6 | 9,550.7 | 0.0 | -326.5 | -- | -37.2 | -- | 6.5 |
Shareholding Pattern
View DetailsAbout PTC Therapeutics (PTCT)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna... and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey. Address: 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059 Read more
-
CEO & Director
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
-
CEO & Director
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
-
Headquarters
Warren, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for PTC Therapeutics (PTCT)
What is the current share price of PTC Therapeutics Inc (PTCT) Today?
The share price of PTC Therapeutics Inc (PTCT) is $70.31 (NASDAQ) as of 19-May-2026 16:00 EDT. PTC Therapeutics Inc (PTCT) has given a return of 6.55% in the last 3 years.
What is the current PB & PE ratio of PTC Therapeutics Inc (PTCT)?
Since, TTM earnings of PTC Therapeutics Inc (PTCT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
8.98
|
-29.85
|
|
2024
|
-9.59
|
-3.17
|
|
2023
|
-3.32
|
-2.54
|
|
2022
|
-4.96
|
-7.99
|
|
2021
|
-5.37
|
1,957.49
|
What is the 52 Week High and Low of PTC Therapeutics Inc (PTCT)?
The 52-week high and low of PTC Therapeutics Inc (PTCT) are Rs 87.50 and Rs 43.18 as of 20-May-2026.
What is the market cap of PTC Therapeutics Inc (PTCT)?
PTC Therapeutics Inc (PTCT) has a market capitalisation of $ 5,928 Mln as on 18-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in PTC Therapeutics Inc (PTCT)?
Before investing in PTC Therapeutics Inc (PTCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.